Announcements Trials
Browse Landscape

Phase

Phase 2 57Phase 1 18Phase 3 14Phase 1/2 13Phase NA 7Phase EARLY_PHASE1 3Phase 4 2

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Plasma cell 3Other hematologic neoplasm 2CNS 2

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Lymphoma 1

Interventions

Cyclophosphamide 10fludarabine 8Dexamethasone 8Lenalidomide 6Bortezomib 5Granulocyte Colony-Stimulating Factor 468Ga-pentixafor 4Melphalan 3Filgrastim 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Blood Specimen Collection 2tocilizumab 1selinexor 1ruxolitinib 1pomalidomide 1pembrolizumab 1methyl prednisolonate 1ixazomib 1ioversol 1inebilizumab 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Filgrastim × Plasma cell × Clear all
NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
21 enrolled
LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT02447055 2016-07-12

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Multiple Myeloma

NCT01537861 2015-01-26

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡